A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Inclusion Criteria:

W8M-MC-LAA2

• Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²)

• Have Type 2 Diabetes

• Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) andtreated with diet and exercise alone or with a stable dose of metformin (and notmore than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening

W8M-MC-CWMM:

• Have had a stable body weight for the 3 months prior to randomization (<5% bodyweight gain and/or loss)

Exclusion Criteria:

W8M-MC-LAA2

• Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6months prior to screening

• Have an on-going or history of bradyarrhythmia and/or sinus bradycardia

• Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reducedresting pulse rate (mean <60 bpm) at screening

• Have any of the following cardiovascular conditions within 6 months prior toscreening:

• acute myocardial infarction

• cerebrovascular accident (stroke)

• unstable angina, or

• hospitalization due to congestive heart failure

• Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45milliliters per minute (mL/min)/1.73 m2

• Have a history of acute or chronic pancreatitis

• Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) atscreening

• All concomitant medications should be at a stable dose for at least 3 months priorto screening

W8M-MC-CWMM

• Have a prior or planned surgical treatment for obesity, except prior liposuction orabdominoplasty, if performed >1 year prior to screening.

• Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history ofketoacidosis or hyperosmolar coma.

• Have poorly controlled hypertension.

• Have a history of symptomatic gallbladder disease within the past 2 years

• Have signs and symptoms of any liver disease other than nonalcoholic fatty liverdisease.

• Have a lifetime history of suicide attempts.